NewLink Genetics Corporation (NLNK) Shares Gap Up on Analyst Upgrade

Shares of NewLink Genetics Corporation (NASDAQ:NLNK) gapped up before the market opened on Monday after Stifel Nicolaus raised their price target on the stock from $14.00 to $29.00. The stock had previously closed at $21.37, but opened at $17.67. Stifel Nicolaus currently has a buy rating on the stock. NewLink Genetics Corporation shares last traded at $16.18, with a volume of 6,516,585 shares.

A number of other research firms have also weighed in on NLNK. Robert W. Baird restated an “outperform” rating and set a $25.00 target price on shares of NewLink Genetics Corporation in a report on Monday, June 5th. ValuEngine upgraded NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a report on Friday, May 19th. Zacks Investment Research lowered NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Jefferies Group LLC restated a “hold” rating and set a $18.00 target price on shares of NewLink Genetics Corporation in a report on Monday, May 15th. Finally, Cantor Fitzgerald set a $26.00 target price on NewLink Genetics Corporation and gave the stock a “buy” rating in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. NewLink Genetics Corporation presently has an average rating of “Buy” and a consensus price target of $24.17.

Several institutional investors and hedge funds have recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its holdings in shares of NewLink Genetics Corporation by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 556 shares during the last quarter. State Street Corp lifted its holdings in shares of NewLink Genetics Corporation by 1.2% during the 2nd quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after purchasing an additional 4,630 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of NewLink Genetics Corporation during the 2nd quarter valued at $286,000. PDT Partners LLC lifted its holdings in shares of NewLink Genetics Corporation by 160.2% during the 2nd quarter. PDT Partners LLC now owns 115,795 shares of the biotechnology company’s stock valued at $851,000 after purchasing an additional 71,295 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of NewLink Genetics Corporation by 40.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 120,767 shares of the biotechnology company’s stock valued at $888,000 after purchasing an additional 34,624 shares during the last quarter. Hedge funds and other institutional investors own 54.78% of the company’s stock.

The company’s 50 day moving average is $7.52 and its 200 day moving average is $12.81. The firm’s market capitalization is $489.57 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The firm had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $2.65 million. Equities research analysts expect that NewLink Genetics Corporation will post ($2.82) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/09/12/newlink-genetics-corporation-nlnk-shares-gap-up-on-analyst-upgrade.html.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply